Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Authors' conclusion
While ipragliflozin and sitagliptin showed similar effects on glycemic parameters, the effects on serum lipid and apolipoprotein profiles were different. Ipragliflozin may have an anti-atherogenic effect through modulation of HDL-C and apo E compared to sitagliptin through TG and apo B48, CII, and CIII in patients with type 2 diabetes.
Study context
- Population
- Patients with T2D (20–74 years old) with HbA1c 7.0–10.5% and serum TG 120–399 mg/dL (1.35–4.50 mmol/L) on diet and/or oral hypoglycemic agents
- Participants
- 77 vs 83
- Comparison
- Ipragliflozin vs sitagliptin
- Ipragliflozinn = 77
- Sitagliptinn = 83reference
- Primary endpoint
- Serum lipid and apolipoprotein profiles
Methodological detailsmulticenter, open-label, Laboratory measurements at 0, 1, 3 and 6 months of treatment
- Multicenter
- Open-label
- Laboratory measurements at 0, 1, 3 and 6 months of treatment
Primary result
As reported in the abstract
- Ipragliflozin increased HDL-C and decreased apo E
- Sitagliptin decreased TG, apo B48, CII and CIII, but increased LDL-C
- Ipragliflozin vs Sitagliptin: P = 0.02
- Ipragliflozin vs Sitagliptin: P = 0.006
- Ipragliflozin vs Sitagliptin: P = 0.06
Further findings
Glycemic parameters (FPG, glycoalbumin, HbA1c)
- Ipragliflozin and sitagliptin reduced FPG, glycoalbumin and HbA1c almost equally
Other clinical parameters
- Ipragliflozin reduced body weight, blood pressure, serum liver enzymes, uric acid and leptin, and increased serum ketones vs sitagliptin
Original publication
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study. Cardiovasc Diabetol. Published 8 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →